Drug Profile


Alternative Names: GP-47779; LIC-477; Licarbazapine

Latest Information Update: 03 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novartis
  • Class Antidepressants; Antimanics; Dibenzazepines; Small molecules
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Bipolar disorders

Most Recent Events

  • 01 Jul 2007 Novartis completes a phase III extension trial in Bipolar I disorders in USA (NCT00228059)
  • 17 May 2005 Phase-III clinical trials in Bipolar disorders in Switzerland (PO)
  • 04 Mar 2004 Phase-II clinical trials in Bipolar disorders in Switzerland (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top